Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02355028 · ClinicalTrials.gov registry record · Phase 2
LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration
A Phase 2 study, sponsored by Alcon, a Novartis Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
NCT02355028: Completed Phase 2 study, sponsored by Alcon, a Novartis Company.
NCT02355028 is a Phase 2 study that has completed, run by Alcon, a Novartis Company. The registered enrollment target is 136 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02355028, a Phase 2 study, has completed, sponsored by Alcon, a Novartis Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of 84 successive days of topically administered LHA510 compared to vehicle in reducing the number of patients requiring intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) therapy (Lucentis®) for recurrence of active choroidal neovascularization (CNV).
Primary Outcome
For subjects who completed the Day 84 visit, retreatment need status was positive if LUCENTIS® retreatment (injection) was required before or at Day 84, including requiring retreatment at or before the Day 84 visit with the actual retreatment performed at a later visit.
Interventions
- DRUG LHA510 ophthalmic suspension
- DRUG LHA510 vehicle
- DRUG Ranibizumab ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2015-03-03 |
| Est. Completion | 2016-10-18 |
| Phase | Phase 2 |
What the finished NCT02355028 record still lists
NCT02355028 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which LHA510 ophthalmic suspension is the first listed.
NCT02355028 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02355028 about?
NCT02355028 is a clinical study titled "LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration". The purpose of this study is to evaluate the efficacy of 84 successive days of topically administered LHA510 compared to vehicle in reducing the number of patients requiring intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) therapy (Lucentis®) for recurrence of active choroidal neova...
What is the current status of trial NCT02355028?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2015-03-03. Estimated completion is 2016-10-18.
What interventions are being tested in trial NCT02355028?
The interventions under investigation include: LHA510 ophthalmic suspension (DRUG), LHA510 vehicle (DRUG), Ranibizumab ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT02355028?
This trial is sponsored by Alcon, a Novartis Company, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02355028's enrollment target sits among peer trials
136 527th of 2000 higher than 1,469 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI